FINITE CHB - First Investigation in Stopping Tenofovir Disoproxil Fumarate (TDF) Treatment After Long Term Virologic Suppression in HBeAg-negative Chronic Hepatitis B.
Phase of Trial: Phase IV
Latest Information Update: 20 Jul 2017
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms FINITE CHB
- Sponsors Gilead Sciences
- 20 Jul 2017 Primary endpoint (Proportion of participants with HBsAg loss at Week 144 in both study arms) has been met,as per the results published in the Journal of Hepatology.
- 20 Jul 2017 Results published in the Journal of Hepatology
- 29 Aug 2016 Status changed from active, no longer recruiting to completed.